MAFbx, MuRF1, and the stress-activated protein kinases are upregulated in muscle cells during total knee arthroplasty

Ashley N. Bailey,1 Austin D. Hocker,1 Benjamin R. Vermillion,1 Keith Smolkowski,2 Steven N. Shah,3 Brian A. Jewett,3 and Hans C. Dreyer1

1Department of Human Physiology, University of Oregon, Eugene, Oregon; 2Oregon Research Institute, Eugene, Oregon; and 3Slocum Center for Orthopedics and Sports Medicine, Eugene, Oregon

Submitted 3 April 2012; accepted in final form 26 June 2012

During total knee arthroplasty (TKA), a tourniquet is routinely placed around the proximal thigh of the operative leg to help ensure rigid bone-implant cementing and to provide the surgeon with a clear surgical field. Previous reports, however, demonstrate that muscle tissue is susceptible to periods of ischemia lasting 15 (1), 30 (1, 39, 42, 43), and 60 min (1, 12, 34, 39, 41), with increasing ischemic times causing more severe tissue injury. It follows then that tourniquet-induced ischemia-reperfusion (I/R) may cause damage to muscle cells during TKA and potentially play a mechanistic role in the rapid, and, more importantly, potentially irrecoverable, muscle loss that results in long-term atrophy-induced functional impairment for these older adults.

We have recently published data demonstrating that proteins regulating cap-dependent translation initiation and elongation were downregulated during and immediately after TKA (36). However, although reductions in muscle protein synthesis can account for the majority of atrophy during disuse, stimulation of muscle protein breakdown, i.e., catabolism, may also occur. Indeed, in our previous report (36), we measured a 12% decrease in midtibial quadriceps volume of the operative (TKA) leg vs. a 6% loss in the nonoperative leg within 2 wk of surgery. We interpreted the differences in the degree of atrophy as potentially being related to the tourniquet-induced I/R injury occurring in the operative (TKA) leg.

Protein synthesis and degradation in skeletal muscle cells are tightly regulated by transcriptional and translational mechanisms (15, 21). These processes define a balance between anabolic and catabolic metabolism and are primarily coordinated through the phosphoinositols 3-kinase (PI3K)/Akt/Forkhead box O3a (FoxO3a) pathways (16). During anabolic conditions, such as with insulin-like growth factor-1 (IGF1) (7), Akt activation of the mammalian target of rapamycin (mTOR) pathway leads to increases in muscle protein synthesis, while under catabolic conditions, such as with glucocorticoids (3) or disuse (37), downregulation of Akt signaling leads to translocation of FoxO3a to the nucleus and upregulation of proteins controlling muscle atrophy (19, 26). Under catabolic conditions, FoxO3a induces the 26S proteasomal pathway by increasing the expression of, in particular, two muscle-specific E3 ubiquitin ligases, muscle atrophy F-box (MAFbx; also known as atrogin 1) and muscle RING finger 1 (MuRF1) (6, 22), which are expressed in all muscle atrophy models. In addition to regulating components of the proteasomal pathway, FoxO3a also regulates the autophagic/lysosomal pathway by binding to sites on the promoters of Bcl2/adenvirus EIB

AS A FUNCTION OF OUR GROWING population of older adults, it is estimated that by 2030, more than 3.4 million total knee replacement surgeries will be performed annually in the United States (24). Despite the near-universal success of total knee replacement in mitigating chronic knee pain due to osteoarthritis, limitations in physical performance and functional mobility persist. Muscle atrophy of the knee extensors has been shown to be the number one contributor to chronic strength deficits, explaining 77% of the strength loss 1–3 years after surgery and is, therefore, the primary reason for chronic limitations (29).
19-kDa-interacting protein 3 (Bnip3) gene. Bnip3 is a proapoptotic member of the Bcl-2 family (28) and has been shown to be upregulated during I/R injury and induction of the autophagic/lysosomal pathway (18). Thus, the Akt/FoxO pathways govern protein catabolism through regulation of the ubiquitin-proteasomal and autophagic/lysosomal pathways.

Our objective, therefore, was to measure transcriptional, translational, and protein changes in the components of the catabolic FoxO3a pathway, i.e., MuRF1, MAFbx, and Bnip3, as well as cell stress pathways, SAPK/JNK and the MAPKs, during TKA. We hypothesized that, in addition to the Akt/4E-BP1 pathway being downregulated (36), the cellular and molecular mechanisms controlling protein catabolism would be upregulated during knee replacement surgery, and as such, help us to further determine how tourniquet-induced I/R injury to muscle cells may contribute to the twofold greater quadriceps atrophy measured in the operative vs. nonoperative leg 2 wk after TKA (36). 

METHODS

Ethics approval. This study was approved by the PeaceHealth Biomedi cal Institutional Review Board, Sacred Heart Medical Center, at River bend and the Biomedical Institutional Review Board for the University of Oregon and conducted in accordance with the Declaration of Helsinki. All subjects gave informed written consent prior to study participation. This study is registered with ClinicalTrials.gov (identifier: NCT00760383).

Subjects. We recruited 12 subjects (8 females and 4 males) between 60 and 80 years of age (average age 70 ± 5 yr) from a pool of surgical candidates from the Slocum Center for Orthopedics and Sports Medicine. All subjects were scheduled to undergo a primary total knee arthroplasty (TKA) and had no current untreated endocrine disease, significant heart, kidney, liver, blood or respiratory disease, peripheral vascular disease, active cancer, recent treatment with anabolic steroids, or oral corticosteroids for greater than 1 wk, and no alcohol or drug abuse. Subject characteristics are provided for each subject in Table 1.

Study design. Details of the study design have been published previously (36). On the morning of surgery, subjects were admitted to Sacred Heart Medical Center at Riverbend in a fasted state. Anesthesia was administered with either a epidural, spinal, or general anesthetic, along with a preoperative femoral nerve block placed for postoperative analgesia. Intravenous propofol was used to induce general anesthesia and was maintained with inhalational anesthetic (either desflurane or sevoflurane), with or without muscle relaxant (rocuronium bromide) (Table 1). A 10-cm-wide Zimmer tourniquet was positioned around the proximal third of the thigh and not inflated. Just before the surgery was ready to begin, the first of three muscle biopsies was obtained from the vastus lateralis muscle on the operative (TKA) leg using a 5-mm Bergström biopsy needle with applied suction, as previously detailed (36) and Fig. 1. Following the first biopsy, the tourniquet was inflated to 300 mmHg or greater, depending on systolic blood pressure to ensure minimal blood flow to the operative leg. A second muscle biopsy was obtained immediately prior to tourniquet deflation, after completion of the main components of the surgery. The tourniquet was then deflated, allowing for reperfusion of the limb with blood. The final muscle biopsy was obtained in the operating room prior to being moved to postoperative recovery. Total tourniquet time (ischemia) was 43 ± 2 min, and reperfusion time was 16 ± 1. Immediately after each biopsy, muscle samples were blotted, and adipose tissue was removed before being frozen in liquid nitrogen (−1°C). Samples were stored in −80°C until analysis, which was routinely performed within 2 wk.

Whole-muscle homogenization. Details for the homogenization procedures have been previously published but have been modified for analysis for this study (10). Frozen muscle samples (25–50 mg)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age</th>
<th>Ht, cm</th>
<th>Wt, kg</th>
<th>BMI, kg/m²</th>
<th>Dx</th>
<th>Medications</th>
<th>Tourniquet Time, min</th>
<th>Reperfusion Time, min</th>
<th>Anesthesia</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>73</td>
<td>171.5</td>
<td>124</td>
<td>42</td>
<td>OA</td>
<td>Enalapril, Furosemide, Norvasc, Prozac, Simvastatin, Travatan, Vincodin</td>
<td>45</td>
<td>21</td>
<td>Gen, FNB</td>
</tr>
<tr>
<td>F</td>
<td>76</td>
<td>165</td>
<td>84</td>
<td>31</td>
<td>OA</td>
<td>Aleve*, nitroglycerine, aspirin, Coreg, Fosinopril, Vytorin, Isosorbide, Furosemide</td>
<td>40</td>
<td>13</td>
<td>Spinal, FNB</td>
</tr>
<tr>
<td>F</td>
<td>70</td>
<td>157.5</td>
<td>73</td>
<td>29</td>
<td>OA</td>
<td>Crestor, Cephalex, Levothyroxin, Aleve, Triamterene/HCTZ</td>
<td>33</td>
<td>16</td>
<td>Spinal, FNB</td>
</tr>
<tr>
<td>M</td>
<td>72</td>
<td>175</td>
<td>100</td>
<td>33</td>
<td>OA</td>
<td>Allopurinol, aspirin*, Amlodipine, Crestor, HCTZ, Metopropol, Norco, Doxazosin, Flomax</td>
<td>53</td>
<td>12</td>
<td>Gen, FNB</td>
</tr>
<tr>
<td>F</td>
<td>79</td>
<td>156</td>
<td>50</td>
<td>21</td>
<td>OA</td>
<td>Triamterene/HCTZ, Viconin, aspirin*, Lovastatin, Omeprazole, Sertraline, Naproxen</td>
<td>44</td>
<td>10</td>
<td>Gen</td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>169</td>
<td>66</td>
<td>23</td>
<td>OA</td>
<td>Percocet, Trazodone, Prednisone, Labetalol, Laxpro, ImiteRx, Lisinopril, Flexeril, Furosemide, Klonopin</td>
<td>38</td>
<td>15</td>
<td>Spinal, FNB</td>
</tr>
<tr>
<td>M</td>
<td>65</td>
<td>170</td>
<td>99</td>
<td>34</td>
<td>OA</td>
<td>Pravastatin, Advil*, Clopidogrel, Diltiazem, Lisinopril HCTZ, Metformin, Novolin</td>
<td>48</td>
<td>25</td>
<td>Gen</td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>157.5</td>
<td>76</td>
<td>31</td>
<td>OA</td>
<td>aspirin, Lisinopril, Triamterene/HCTZ, Naproxen, Prilosec</td>
<td>49</td>
<td>11</td>
<td>Gen, FNB</td>
</tr>
<tr>
<td>F</td>
<td>69</td>
<td>150</td>
<td>91</td>
<td>40</td>
<td>OA</td>
<td>spiranolactone, Verapamil, Ropinirole, Simvastatin, Amlodipine, aspirin, Citalopram, Cozaar, Gabapenton, Glipizide, Humulin, Prilosec, oxyccodone, Vincodin</td>
<td>42</td>
<td>22</td>
<td>Gen</td>
</tr>
<tr>
<td>F</td>
<td>69</td>
<td>155</td>
<td>64</td>
<td>27</td>
<td>OA</td>
<td>Lovaza, alpha lipoic acid, Tylenol, Percocet, Ambien, Rantidine, Plavix, Lyrica</td>
<td>45</td>
<td>15</td>
<td>Gen, FNB</td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>157.5</td>
<td>81</td>
<td>33</td>
<td>OA</td>
<td>Allopurinol, Furosemide, Omeprazole, Simvastatin, Tylenol</td>
<td>34</td>
<td>18</td>
<td>Gen</td>
</tr>
<tr>
<td>M</td>
<td>68</td>
<td>180</td>
<td>100</td>
<td>31</td>
<td>OA</td>
<td>Enalapril, HCTZ, Lipitor, Norco, Zolpidem</td>
<td>42</td>
<td>11</td>
<td>Gen, FNB</td>
</tr>
</tbody>
</table>

*Medication withheld week prior to surgery. Dx, diagnosis; OA, osteoarthritis; FNB, femoral nerve block; Gen, general anesthesia; Spinal, spinal anesthesia; Epd, epidural anesthesia. Femoral nerve block: 30 ml of 0.25% to 0.5% bupivacaine or ropivacaine. General anesthesia: intravenous propofol and maintained by inhalation of either desflurane or sevoflurane. Spinal anesthesia: 0.75% bupivacaine + 20 µg of fentanyl. Epidural anesthesia: 0.25% bupivacaine. Muscle relaxant: Administered by local injection of rocuronium bromide.

AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00146.2012 • www.ajpregu.org
were crushed using Heidolph Brinkmann Silent Crusher M in homogenization (1:9, w/v) buffer containing: 50 mM Tris·HCl, 250 mM mannitol, 50 mM Na pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1% SDS-PAGE and immunoblotting.

Details of the immunoblotting procedures have been previously published (36), with specific modifications implemented for this study. Homogenates were loaded in duplicate using a Qubit Protein Assay Kit (no. Q3321; Invitrogen, Carlsbad, CA) on a Qubit 2.0 Fluorometer (Invitrogen).

Nuclear and cytoplasmic homogenization and fractionation. Isolation of nuclear and cytoplasmic fractions was done using the NE-PER kit (no. 78835; Thermo Fisher Scientific, Waltham, MA). Frozen muscle samples (25–50 mg) were washed with 1× TBS and then homogenized in cytoplasmic extraction reagent I containing 0.5 mM PMSF. Homogenates were then vortexed and incubated on ice for 10 min. Cytoplasmic extraction reagent II was added to the samples, vortexed, and centrifuged at 16,000 g for 30 min to isolate 4E-BP1. Protein concentration (mg/ml) was determined in duplicate using a Qubit Protein Assay Kit (no. Q3321; Invitrogen, Carlsbad, CA) on a Qubit 2.0 Fluorometer (Invitrogen).

Nuclear and cytoplasmic homogenization and fractionation. Isolation of nuclear and cytoplasmic fractions was done using the NE-PER kit (no. 78835; Thermo Fisher Scientific, Waltham, MA). Frozen muscle samples (25–50 mg) were washed with 1× TBS and then homogenized in cytoplasmic extraction reagent I containing 0.5 mM PMSF. Homogenates were then vortexed and incubated on ice for 10 min. Cytoplasmic extraction reagent II was added to the samples, vortexed, and centrifuged at 16,000 g for 4°C for 30 min to isolate 4E-BP1. Protein concentration (mg/ml) was determined in duplicate using a Qubit Protein Assay Kit (no. Q3321; Invitrogen, Carlsbad, CA) on a Qubit 2.0 Fluorometer (Invitrogen).

Nuclear and cytoplasmic homogenization and fractionation. Isolation of nuclear and cytoplasmic fractions was done using the NE-PER kit (no. 78835; Thermo Fisher Scientific, Waltham, MA). Frozen muscle samples (25–50 mg) were washed with 1× TBS and then homogenized in cytoplasmic extraction reagent I containing 0.5 mM PMSF. Homogenates were then vortexed and incubated on ice for 10 min. Cytoplasmic extraction reagent II was added to the samples, vortexed, and centrifuged at 16,000 g for 4°C for 30 min to isolate 4E-BP1. Protein concentration (mg/ml) was determined in duplicate using a Qubit Protein Assay Kit (no. Q3321; Invitrogen, Carlsbad, CA) on a Qubit 2.0 Fluorometer (Invitrogen). Adequate separation of cytoplasmic and nuclear fractions was confirmed via Western blot detection of α-tubulin (cytoplasmic protein) and laminin A/C (nuclear protein) (Fig. 2).

**SDS-PAGE and immunoblotting.** Details of the immunoblotting procedures have been previously published (36), with specific modifications implemented for this study. Homogenates were loaded in duplicate into TGX all kD precast gels (Bio-Rad) in electrode buffer (0.3% Tris base, 14.4% glycine, 1% SDS in dd-H2O). A single muscle homogenate sample was loaded in duplicate with each gel and used as a between-blot internal loading control (Fig. 2).

**Total RNA isolation and cDNA synthesis.** Details for RNA isolation have been previously published (36) with slight modifications implemented for this study. Skeletal muscle samples (10–20 mg) were homogenized in 1 ml TRI Reagent using Heidolph Brinkmann’s Silent Crusher M at 10,000–15,000 rpm in Eppendorf RNase-free tubes. Separation was achieved through the addition of 0.2 ml of chloroform and precipitation with 0.5 ml isopropanol. The RNA pellet was washed twice in 75% ethanol, dried, and then dissolved in 1.5 μl of 0.1 mM EDTA for each 1 mg of starting tissue. RNA concentrations were determined using a Qubit fluorometer (Invitrogen, Carlsbad, CA), and cDNA was reverse transcribed from 1 μg RNA on a CFX96 real-time PCR Detection System (Bio-Rad) using iScript Reaction Mix (Bio-Rad), according to manufacturer’s instructions and stored at –80°C for analysis.

**Oligonucleotide primers for qPCR.** Oligonucleotide primers were designed using Beacon Design software (ver. 7.91), specific to our Bio-Rad CFX96 real-time PCR Detection System, based on NCBI Entrez Gene ID search results. Primer efficiencies were determined through analysis of four serial dilutions, analyzed in triplicate on a run in triplicate log linear scale: efficiency = 10^(-1/slope). Efficiencies were in accordance with MIQE guidelines (0.95 and 1.05) for all primer pairs (8). Primers were designed for α-tubulin (NM_006082; Fwd: AGATGCT-GCCAATACTATG, Rev: AATTCCGTCCACACAAAG); β-tubulin (NM_030773; Fwd: CAGTTGCTCTTCTCAGTT, Rev: GAT-TACGCCTTTGTGATT); β-2-microglobulin (NM_004048; Fwd: TCTCTTATTCACAATCATCTT, Rev: GCACGCTTAAC-TATCTTACACAG); Forkhead box O3 (FOXO3) (NM_001455; Fwd: GCATCTCTACTGAGGATT, Rev: ACACAGGCAATATCTAC).
atrogin-1 (MAFbx) (NM_058229; Fwd: TGGATGGGAAGAAGATG- TAT, Rev: AAAGGATGTGACAGTGTT); muscle ring finger (MuRF) (NM_032588; Fwd: ATGAGGAAGGAAGAATT, Rev: CT- TACTGTTGTCCTCTTT); activating transcription factor (ATF4) (NM_001675; Fwd: AGATAGGAAGCAGACTA, Rev: CTCATA- CAGATGCACACTA); Jun N-terminal kinase (JNK) (NM_002750; Fwd: TAGTGTAGAGATTGGAGATT, Rev: AAGAATGGCATCATA- AGC); p-38α (NM_001315; Fwd: GTTCAGTTCTTATCTTACA, Rev: GCCTCAGTTCTTATTCA); BCL2/adenovirus E1B 19-kDa protein-binding protein 3 (Bnip3) (NM_004052; Fwd: TCATAATCAA- CAGAAACCAG, Rev: ATCACCTATAATCGGAGACT); B-cell lymphoma 2 (BCL2) (NM_006538; Fwd: ATATCTGCCTGTATCTTG, Rev: TCTGTTGTTATTACTGCTA); and JunB proto-oncogene (JUNB) (NM_002229; Fwd: GAACACCTTCTATGAC, Rev: GGTTACTG- TAGCCATAG).

mRNA quantitation by qPCR. Details on qPCR have been previously published (36), with specific modifications employed for this study. Samples of cDNA were analyzed using SYBR Green fluorescence (iQ SYBR Green Supermix; Bio-Rad, Hercules, CA). Each reaction contained 12.5 µl SYBR Green, 9.5 µl DEPC-treated nuclease-free water, 0.5 µl forward and 0.5 µl reverse primers, and 2 µl of cDNA template, and was prepared in triplicate. An initial 5-min cycle at 95°C was used to denature the cDNA. This was followed with 50 PCR cycles consisting of denaturation at 95°C for 10 s followed by 30 s of primer annealing at the optimized primer pair-annealing temperature. All PCR cycles were followed by a melt curve analysis.

Fig. 3. Protein translation downregulation during total knee arthroplasty (TKA). Data represent Akt at Ser-473 in whole muscle fraction (A) (n = 6); 4E-BP1 Thr-36/47 (B); eukaryotic initiation factor 4E (eIF-4E) at Ser-209 in the cytoplasmic (C) and nuclear fraction (D). Representative phosphorylated, total, and loading control (Ponceau) Western blot are included. Data are expressed as means ± SE (n = 10). *P ≤ 0.05 vs. baseline.
Fig. 4. Stress pathway during TKA. Stress-activated protein kinase (SAPK/JNK) protein in the cytoplasmic (A) and nuclear fraction (B). MAPK p-38α protein in the cytoplasmic (C) and nuclear fraction (D). MAPK p-38β protein in the cytoplasmic (E) and nuclear fraction (F). Representative phosphorylated, total, and loading control (Ponceau) Western blot are included. Data are expressed as means ± SE (n = 10). *P ≤ 0.05 vs. baseline.
Each gene of interest (GOI) was normalized to the geometric mean of select genes of reference (GOR); α-tubulin, β-tubulin, and β-2-microglobulin. Data for each GOI are expressed as fold change relative to the GOR using the Livak method, also known as the 2-ΔΔCT method (27): ΔCT(test) = CT(GOI, test) − CT(GOR, test) ΔCT(baseline) = ΔCT(test) − ΔCT(baseline) 2-ΔΔCT = fold change from baseline.

Statistical analysis. Statistical evaluation of our data was performed using a repeated-measures ANOVA to compare ischemic and reperfusion samples to baseline. Differences between means were considered significant at $P \leq 0.05$. Differences between means were considered a trend at $P \leq 0.10$. Analysis for all variables was performed using SAS Institute (2009), Base SAS 9.2. All values are expressed as means ± SE, unless otherwise stated.

RESULTS

Demographics. Male and female subject characteristics were not different for age, height, weight, and body mass index ($P > 0.05$); data for all subjects are in Table 1. The average age for our cohort was 70 ± 1.3 yr. The average height, weight, and BMI was 164 ± 2.7 cm, 84 ± 5.8 kg, and 31 ± 1.8 kg/m², respectively.

Cell signaling. Adequate tissue samples from all three biopsies were available for only six subjects for the analysis of whole muscle fractions. These samples were used to confirm our previous results (36). Relative to baseline, phosphorylation of Akt at Ser-473 decreased by 43% during ischemia ($F = 13.71$) ($P = 0.013$, 80% CI $[-72\%, -31\%]$) but was not significant during reperfusion $-20\%$ ($F = 5.95$) ($P = 0.08$, 80% CI $[-51\%, -13\%]$) (Fig. 3A).

There was adequate tissue to analyze cytoplasmic and nuclear protein fractions for 10 subjects. Relative to baseline eukaryotic initiation factor 4E binding protein (4E-BP1) phosphorylation at Thr-37/46/total 4E-BP1 was significantly decreased by 30% ($F = 16.36$) ($P = 0.003$, 80% CI $[-26\%$,

![Fig. 5. Autophagic/lysosomal pathway during TKA. Bcl2 protein in the cytoplasmic (A) and nuclear fraction (B). Bcl2 adenovirus EIB 19-kDa-interacting protein 3 (Bnip3) protein in the cytoplasmic (C) and nuclear fraction (D). Representative phosphorylated, total, and loading control (Ponceau) Western blot images are included. Data are expressed as means ± SE ($n = 10$). *$P \leq 0.05$ vs. baseline.](http://ajpregu.physiology.org/)
and 27% (F = 5.57) (P = 0.043, 80% CI [−30%, −8%]) during ischemia and reperfusion, respectively in the cytoplasmic fractions (Fig. 3B). Relative to baseline, eIF-4E at Ser-209 increased significantly in the cytoplasmic fraction during ischemia, by 189% (F = 6.54) (P = 0.031, 80% CI [54%, 182%]) but was not significantly different from baseline during reperfusion (Fig. 3C). Relative to baseline, eIF-4E phosphorylation in the nuclear fraction did not change during ischemia or reperfusion (Fig. 3D).

Relative to baseline, SAPK/JNK protein significantly increased in the cytoplasmic fraction during ischemia by 27% (F = 24.12) (P = 0.001, 80% CI [24%, 43%]) (Fig. 4A), while in the nuclear fraction, there was a trend to decrease during reperfusion, −21% (F = 4.24) (P = 0.073, 80% CI [−24%, −5%]) but was not significant (Fig. 4B). Relative to baseline, p-38 protein did not change in the cytoplasmic fraction during ischemia (Fig. 4C), while in the nuclear fraction, there was a trend for it to increase during ischemia by 34% (F = 3.95) (P = 0.082, 80% CI [5%, 30%]) but was not significant, while during reperfusion, it was significantly decreased by 18% (F = 9.42) (P = 0.015, 80% CI [−17%, −6%]) (Fig. 4D). Relative to baseline, p-38 protein tended to increase in the cytoplasmic fraction during ischemia by 33% (F = 4.12) (P = 0.073, 80% CI [16%, 263%]) but was not significant (Fig. 4E), while in the nuclear fraction, there was a significant increase during ischemia by 25% (F = 9.55) (P = 0.015, 80% CI [5%, 30%]) (Fig. 4F).

Relative to baseline, Bcl2 protein showed a trend to increase in the cytoplasmic fraction during ischemia by 97% (F = 5.10) (P = 0.054, 80% CI [62%, 263%]) but was not significant (Fig. 5A), while in the nuclear fraction, there was no change (Fig. 5B). Bcl2/adenovirus EIB 19-kDa-interacting protein 3 (Bnip3) protein

Fig. 6. E3 ubiquitin proteasomal pathway during TKA. MAFbx protein in the cytoplasmic (A) and nuclear fraction (B). MuRF1 protein in the cytoplasmic (C) and nuclear fraction (D). Representative phosphorylated, total, and loading control (Ponceau) Western blot images are included. Data are expressed as means ± SE (n = 10). *P ≤ 0.05 vs. baseline.

AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00146.2012 • www.ajpregu.org
levels did not change in the cytoplasmic fraction during ischemia or reperfusion (Fig. 5C). Bnip3 protein levels in the nuclear fraction significantly decreased during reperfusion by 22% \((F = 6.60) [P = 0.033, 80\% CI (-139\%, -41\%)]\) (Fig. 5D). We did not detect significant changes in phosphorylation status in the cytoplasmic or nuclear fractions for p-GSK3\(\beta\) Ser-9; however, we did detect a significant increase in GSK3\(\beta\) total protein during ischemia \(42\% \quad (F = 8.26) \quad [P = 0.018, 80\% CI (21\%, 60\%)]\).

Relative to baseline, the E3 ubiquitin ligase atrogin-1/MAFbx protein increased in the cytoplasmic fraction during ischemia by \(30\% \quad (F = 18.30) \quad [P = 0.002, 80\% CI (15\%, 29\%)]\) (Fig. 6A), while the nuclear fraction significantly decreased during reperfusion by \(30\% \quad (F = 5.80) \quad (P = 0.043, 80\% CI [-97\%, -26\%])\) (Fig. 6B). As well, relative to baseline, MuRF1 protein increased in the cytoplasmic fraction during ischemia by \(53\% \quad (F = 26.33) \quad [P = 0.0006, 80\% CI (36\%, 62\%)]\) and remained elevated during reperfusion \(31\% \quad (F = 18.36) \quad [P = 0.002, 80\% CI (18\%, 36\%)]\) (Fig. 6C). In the nuclear fraction, MuRF1 protein tended to decrease during reperfusion, by \(29\% \quad (F = 4.21) \quad [P = 0.074, 80\% CI (-106\%, -20\%)]\) but was not significant (Fig. 6D).

**Gene expression.** Adequate tissue was available to analyze gene expression for seven subjects. Relative to baseline, FoxO3a mRNA increased during ischemia by \(157\% \quad (F = 18.55) \quad [P = 0.008, 80\% CI (66\%, 135\%)]\) (Fig. 7A). Relative
to baseline, the E3 ubiquitin ligase MAFbx mRNA increased during ischemia by 237% \((F = 7.37) [P = 0.042, 80\% \text{ CI (85\%, 288\%) }\) (Fig. 7F). As well, MuRF mRNA increased during ischemia by 288% \((F = 7.75) [P = 0.039, 80\% \text{ CI (161\%, 380\%) }\) (Fig. 7C). Relative to baseline, SAPK/JNK mRNA increased during ischemia by 169% \((F = 15.16) [P = 0.012, 80\% \text{ CI (95\%, 211\%) }\) (Fig. 7D) and p-38α mRNA increased during ischemia 173% \((F = 21.80) [P = 0.006, 80\% \text{ CI (125\%, 242\%) }\) (Fig. 7E). We did not detect significant changes in transcript levels for Bnip3 and Bcl2.

**DISCUSSION**

I/R occurs each time a tourniquet is used to control blood flow during surgeries, such as TKA. However, the cellular and molecular alterations associated with I/R remain to be fully elucidated. We have recently reported that proteins regulating components of the cap-dependent translation initiation and elongation complex are downregulated with I/R during TKA (36). However, at the cellular level, atrophy is defined by the imbalance between proteins controlling both muscle anabolism and catabolism. Our objective, therefore, was to measure changes in the components of the catabolic FoxO3a pathway, as well as cell stress pathways, during TKA. We hypothesized that cellular mechanisms controlling muscle protein catabolism would be upregulated during surgery, and as such, help us to further determine how I/R injury may potentially contribute to the twofold greater quadriceps atrophy measured in the operative vs. nonoperative leg 2 wk after TKA (36).

This study reveals several important and novel findings regarding the acute effects of I/R in stimulating pathways known to play key roles in protein catabolism in muscle cells (Fig. 8). First, we confirm previous findings obtained by our group (36), showing that the Akt/4E-BP1 pathway is downregulated during ischemia and reperfusion and add further to those findings by including the phosphorylation status of the eIF-4E. Second, we found that protein levels for MuRF and MAFbx, two downstream components of FoxO3a pathway, were upregulated during ischemia but only protein levels for MuRF remained elevated through reperfusion. Third, we measured an increased expression of the SAPK/JNK and the p-38 mitogen activated protein kinase (p-38 MAPK α/β). To our knowledge, this study is the first to measure simultaneous changes in key regulatory proteins known to exert control over both the anabolic and catabolic transcriptional and signaling pathways in skeletal muscle cells during TKA.

4E-BP1’s binding target eIF-4E showed no changes in the total amount of protein present, but there were measurable changes in phosphorylation in the cytoplasmic fraction during ischemia. eIF-4E phosphorylation at Ser-209 was first thought to enhance its binding to the 5’-cap, but it is now believed that phosphorylation of eIF-4E may have the opposite effect, decreasing its binding affinity (30, 38, 40). Mitogen- or stress- and cytokine-activated signaling regulates eIF-4E phosphorylation to a greater extent than anabolic stimuli (33), and the significance of its phosphorylation is largely undetermined in mammals. It is possible that eIF-4E phosphorylation during...
MAFbx AND MuRF1 ACTIVATION DURING TKA

TKA is necessary to increase the translation of proapoptotic transcripts that are upregulated during I/R. Downregulation of Akt leads to dephosphorylation of FoxO3a and translocation into the nucleus, where it promotes the transcription of atrophy-related genes (2). FoxO3a may also be acted upon by the SAPK/JNK pathway. We measured an increase in SAPK/JNK transcript levels and protein concentrations in the cytoplasm during ischemia. Activation of the SAPK/JNK pathway under these conditions is consistent with, and suggests a role for, oxidative stress as a potential stimulating factor initiating the upregulation of the catabolic SAPK/JNK/FoxO pathway (13).

Cytoplasmic protein levels for MuRF1 increased during both ischemia and reperfusion, while MAFbx protein increased only during ischemia. Interestingly, we measured a significant decrease in MAFbx protein in the nuclear fraction during reperfusion which did not appear to mirror reciprocal changes in the cytoplasmic fraction. Previous research has found that MAFbx contains two nuclear localization signals (NLS), which are each sufficient to signal MAFbx translocation into the nucleus (17, 20). We are not sure of the physiological consequences for the decrease in the nuclear fraction but MAFbx cytoplasmic-nuclear shuttling has been shown to occur in myotubes subjected to catabolic conditions (25). It remains that additional work is needed to further define a role for MAFbx colocalization in and out of the nucleus during I/R injury.

The primary function of the Bcl-2 proteins is in the regulation, and stabilization of, the outer mitochondrial membrane (9, 23). While not statistically significant, our data suggest that Bcl-2 protein levels tended to increase in the cytoplasmic fraction during ischemia ($P = 0.054$), which may be in response to I/R induced oxidative stress as suggested by our p-38β data and hold potential clinical relevance in terms of mitochondrial involvement in respiratory function during tourniquet use. We measured an increase in p-38β in the nuclear fraction during ischemia. It has been shown that p-38 protein colocalizes within the nuclear fraction at rest and translocates to the cytosol upon stimulation (5). Stress-activated p-38 has been shown to bind to and inhibit extracellular signal-regulated kinases 1/2 (ERK1/2), i.e., MAP kinases, which are activated to varying degrees by cytokines, growth factors, and osmotic and other types of cell stress (35). Further research is required in order for us to better understand the contributions of the rapid changes in nuclear and cytoplasmic fractions and how these alterations impact muscle metabolism in the hours and days following TKA.

Our study is limited by the lack of a non-tourniquet control group matched for surgery duration and anesthesia administration. Additionally, we were unable to control for the various preoperative and perioperative medications, analgesics, and muscle relaxants, as well as for levels of physical activity prior to surgery, and we do not have a direct measure of protein synthesis or degradation. As such, we acknowledge the need for further intraoperative and perioperative studies designed to quantify the magnitude of the contribution of I/R injury on muscle protein breakdown.

Perspectives and Significance

Despite the considerable success of TKA in mitigating knee pain due to osteoarthritis, chronic limitations in functional mobility remain and are primarily due to irrecoverable quadriceps muscle loss. Indeed, quadriceps atrophy is the main contributor to long-term strength deficits (29), and by far the most significant long-term clinical barrier following TKA surgery is persistent muscle atrophy (14, 31, 44). Broadly speaking, acute muscle loss for older adults represents an acceleration of sarcopenia, i.e., the gradual $\sim$1%/year of muscle lost due to aging, per se (11). In other words, a 12% loss in quadriceps volume occurring within 2 wk of surgery (36) would represent $\sim$12 yr of “normal” aging. This “accelerated sarcopenic muscle loss” (32) is potentially devastating for older women who, compared with older men, demonstrate a blunted capacity to increase muscle volume (4).

In conclusion, we interpret our findings to support our hypothesis that factors resulting from ischemia are sufficient to upregulate components of the FoxO3a catabolic pathway during TKA and that cellular stress pathways may play a role in stimulating this response. These data extend our understanding of the effects of I/R to now include proteins regulating anabolic (36), as well as catabolic and stress-activated, pathways being altered during TKA. Additional studies are necessary to better understand the mechanisms underlying the rapid-onset muscle atrophy that occurs within weeks of this surgery and, in particular, the means by which potentially irrecoverable muscle atrophy may be avoided in older women.

ACKNOWLEDGMENTS

We thank Crystal Mills and Alicia Morrison of the Slocum Center for Orthopedics & Sports Medicine for their help with the recruitment and scheduling. We would also like to thank Joni Strub, OR Nurse Manager, and the surgical staff at Sacred Heart Medical Center at RiverBend, as well as the anesthesiologists from Northwest Anesthesia Physicians group for their assistance with the study. We thank Hilary Senesac and Steven Ratchford for assistance with tissue collection.

Patients were recruited at the Slocum Center for Orthopedics and Sports Medicine, Eugene, OR. Surgeries and tissue collection were conducted at the Sacred Heart Medical Center, Riverbend, Springfield, OR. Processing and analysis of all tissue samples were performed in the Muscle Physiology Laboratory at the University of Oregon, Eugene, OR.

GRANTS

This study was supported by the National Center for Medical Rehabilitation and Research, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health Grant K01HD57332 (H. C. Dreyer). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES


